Kawada Tatsushi, Yanagisawa Takafumi, Rajwa Pawel, Motlagh Reza Sari, Mostafaei Hadi, Quhal Fahad, Laukhtina Ekaterina, Pallauf Maximilian, König Frederik, Pradere Benjamin, Araki Motoo, Nasu Yasutomo, Shariat Shahrokh F
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Kita-ku, Okayama, Japan.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Clin Genitourin Cancer. 2024 Apr;22(2):535-543.e4. doi: 10.1016/j.clgc.2024.01.008. Epub 2024 Jan 17.
We aimed to assess the prognostic value of tumor infiltrating lymphocytes (TILs) in patients with bladder cancer (BC) after radical cystectomy (RC).
We searched Pubmed, Web of Science and Scopus in April 2022 to identify studies assessing the prognostic value of TILs, including a subset of lymphocytes (eg, CD3, CD8, FOXP3), after RC. The endpoints were overall survival and recurrent free survival. Subgroup analyses were performed based on the evaluation method for TILs (ie, CD3, CD8, FOXP3, HE staining).
Overall, 9 studies comprising 1413 patients were included in this meta-analysis. The meta-analysis revealed that elevated expressions of TILs were significantly associated with favorable OS (pooled hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.51-0.83) and RFS (pooled HR: 0.48, 95% CI: 0.35-0.64). In subgroup analyses, high CD8+ TILs were also associated with favorable OS (HR: 0.51, 95% CI: 0.33-0.80) and RFS (pooled HR: 0.53, 95% CI: 0.36-0.76). Among 3 studies comprising 146 patients, high intratumoral TILs were significantly associated with favorable OS (pooled HR: 0.34, 95% CI: 0.19-0.60).
TILs are useful prognostic markers in patients treated with RC for BC. Although the prognostic value of TILs is varied, depending on the subset and infiltration site, CD8+ TILs and intratumoral TILs are associated with oncologic outcomes. Further studies are warranted to explicate the predictive value of TILs on the response to perioperative systemic therapy to help clinical decision-making in patients with BC.
我们旨在评估根治性膀胱切除术后膀胱癌患者肿瘤浸润淋巴细胞(TILs)的预后价值。
我们于2022年4月检索了PubMed、Web of Science和Scopus,以识别评估根治性膀胱切除术后TILs(包括淋巴细胞亚群,如CD3、CD8、FOXP3)预后价值的研究。终点指标为总生存期和无复发生存期。根据TILs的评估方法(即CD3、CD8、FOXP3、苏木精-伊红染色)进行亚组分析。
总体而言,本荟萃分析纳入了9项研究,共1413例患者。荟萃分析显示,TILs表达升高与良好的总生存期(合并风险比[HR]:0.65,95%置信区间[CI]:0.51-0.83)和无复发生存期(合并HR:0.48,95%CI:0.35-0.64)显著相关。在亚组分析中,高CD8+TILs也与良好的总生存期(HR:0.51,95%CI:0.33-0.80)和无复发生存期(合并HR:0.53,95%CI:0.36-0.76)相关。在包含146例患者的3项研究中,高肿瘤内TILs与良好的总生存期显著相关(合并HR:0.34,95%CI:0.19-0.60)。
TILs是接受根治性膀胱切除术治疗的膀胱癌患者有用的预后标志物。尽管TILs的预后价值因亚群和浸润部位而异,但CD8+TILs和肿瘤内TILs与肿瘤学结局相关。有必要进一步研究以阐明TILs对围手术期全身治疗反应的预测价值,以帮助膀胱癌患者的临床决策。